Table 1 Responses to the question about criteria for the indication of augmentation therapy for alpha-1 antitrypsin deficiency (n, %)
Spain | Portugal | P value | PUL | IMS | PCP | P value | Total | |
|---|---|---|---|---|---|---|---|---|
N = 221 | N = 155 | N = 100 | N = 100 | N = 176 | N = 376 | |||
Severe AATD | 190 (86.0) | 103 (66.5) | <0.001 | 96 (96.0) | 77 (77.0) | 120 (68.2) | <0.001 | 293 (77.9.0) |
Emphysema | 146 (66.1) | 69 (44.5) | 0.001 | 71 (71.0) | 55 (55.0) | 89 (50.6) | 0.004 | 215 (57.2) |
FEV1 | 99 (44.0) | 54 (34.8) | NS | 63 (63.0) | 36 (36.0) | 54 (30.7) | <0.001 | 153 (40.7) |
-<=35 % | 28 (12.7) | 17 (11.0) | NS | 20 (20.0) | 12 (12.0) | 13 (7.4) | 0.008 | 45 (12.0) |
-36–60 % | 71 (32.1) | 25 (16.1) | 0.001 | 42 (42.0) | 18 (18.0) | 36 (20.6) | <0.001 | 96 (25.5) |
-61–80 % | 7 (7.7) | 16 (10.3) | NS | 17 (17.0) | 8 (8.0) | 8 (4.5) | <0.001 | 33 (8.7) |
Non smoker | 99 (44.8) | 56 (36.1) | NS | 72 (72.0) | 33 (33.0) | 50 (28.1) | <0.001 | 155 (41.2) |
Liver disease | 80 (36.2) | 42 (27.1) | NS | 33 (33.0) | 40 (40.0) | 49 (27.1) | NS | 122 (32.4) |
Age >18 years | 65 (29.4) | 46 (29.7) | NS | 46 (46.0) | 23 (23.0) | 42 (23.9) | <0.001 | 111 (29.5) |